Blood collection

PreclinicalBiologic

AAssistance Publique - Hôpitaux de Paris

Blood collection is one of 312 biologic programs targeting Aspergillosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

311

Competitors

Pipeline

Status by Indication[3][1]

Indication

AspergillosisActive, not recruiting

Kidney CancerActive, not recruiting

HepatitisActive, not recruiting

Pulmonary EdemaActive, not recruiting

Colorectal CancerActive, not recruiting

MigraineActive, not recruiting

COVID-19Active, not recruiting

AsthmaActive, not recruiting

Ankylosing SpondylitisActive, not recruiting

DementiaActive, not recruiting

AspergillosisPreclinical

Active, not recruiting

Kidney CancerPreclinical

Active, not recruiting

HepatitisPreclinical

Active, not recruiting

Pulmonary EdemaPreclinical

Active, not recruiting

Colorectal CancerPreclinical

Active, not recruiting

MigrainePreclinical

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

AsthmaPreclinical

Active, not recruiting

Ankylosing SpondylitisPreclinical

Active, not recruiting

DementiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

COVID-19 Vaccine

Moderna

Preclinical

27 2

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 3

Rayaldee

OOrganon and Co

Preclinical

1 4

Aquasol E

NNational Eye Institute (NEI)

Preclinical

1 5

Tricor

JJagotec

Preclinical

1 6

Benadryl

PParkedale

Preclinical

1 7

Nitrostat

VViatris Specialty LLC

Preclinical

1 8

Orap

Teva

Preclinical

1 9

Biological Data

UUniversity Hospital, Bordeaux

Preclinical

3 10

Olokizumab

UCB

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

N/ARecruiting

Pulmonary Edema

NCT05049889

Q2 2027

N/ANot yet recruiting

Antibody

NCT06373510

Q1 2028

Recruiting

Migraine

NCT07177885

Q1 2029

Recruiting

Rejection

NCT07134491

Clinical

Trials by Indication[1]

Age2 trials

Effects of Silica and Asbestos Fibres on the Efferocytosis Capacities of Macrophages

Completed·RRennes University Hospital·N/A·NCT04473742·23 enrolled

Macrophages, GM-CSF and MARS Proteinosis

Completed·AAssistance Publique - Hôpitaux de Paris··NCT04811274·20 enrolled

Antibody1 trial

Longitudinal Evaluation of Antibody Kinetics of Vaccinated Patients With Non-mandatory Vaccine Following Administration of a Non-public Marketed Vaccine in the General Population, Real-life Study

Not yet recruiting·CCerbaXpert·N/A·NCT06373510·10,000 enrolled

Dementia1 trial

Biomarkers of Dementia in Chronic Sleep and Breathing Disorders

Unknown status·WWoolcock Institute of Medical Research··NCT06377332·104 enrolled

Ankylosing Spondylitis1 trial

Ankylosing Spondylitis and Antiphospholipid Antibodies

Unknown status·CCHU de Reims·N/A·NCT02809300·80 enrolled

Rejection1 trial

Peripheral and Intrarenal B Cell Study in Antibody Mediated Transplant Rejection : Phenotypic and Transcriptional Study, Study of Reactivity

Recruiting·AAssistance Publique - Hôpitaux de Paris··NCT07134491·45 enrolled

16 more indications

Children1 trial

Determine Immunoglobulin G4 (IgG4) Standards for Cow's Milk and Egg in Different Populations of Allergic and Non-allergic Children

Recruiting·AAssistance Publique - Hôpitaux de Paris··NCT03776474·500 enrolled

Hepatitis1 trial

Assessment of the Predictive Value of Fecal Calprotectin for the Outcome of Severe Alcoholic Hepatitis

Completed·CCHU de Reims·N/A·NCT02808663·6 enrolled

Pulmonary Edema1 trial

Screening for Individual Susceptibility Factors to Immersion Pulmonary Edema

Recruiting·DDirection Centrale du Service de Santé des Armées·N/A·NCT05049889·63 enrolled

Migraine1 trial

Tryptophan as a Modulating Factor in the Antimigraine Efficacy of Triptans

Recruiting·UUniversity Hospital, Clermont-Ferrand··NCT07177885·144 enrolled

Completed·—··NCT04659018·30 enrolled

Antidepressants1 trial

Evaluation of the Relevance of Pharmacogenetics in the Prescription Off Antidepressants in a Military Population

Unknown status·DDirection Centrale du Service de Santé des Armées··NCT04987047·250 enrolled

Idiopathic Parkinson's Disease1 trial

Multicenter Study of Blood Biomarkers of Mitochondrial and Peroxisomal Metabolism to Differentiate Idiopathic Parkinson's Disease From Related Conditions

Unknown status·—··NCT05110547·75 enrolled

Aspergillosis1 trial

PET/CT Guided Antifungal Stewardship in Invasive Pulmonary Aspergillosis

Completed·AAssistance Publique - Hôpitaux de Paris·N/A·NCT02955966·51 enrolled

Efficacy1 trial

Efficacy of Milk Product Supplemented With Bioactives in Lowering Post Meal Glucose Response

Completed·SSociété des Produits Nestlé (SPN)·N/A·NCT05570435·31 enrolled

Paclitaxel1 trial

Weekly Paclitaxel and Cyclophosphamide in Metronomic Administration : Dose Escalation Study of Weekly Paclitaxel

Completed·CCentre Oscar Lambret·Phase 1·NCT01374620·28 enrolled

COVID-191 trial

Study of Kinetics and Efficacy of the Immune Response Against COVID-19 Among Hospital Staff

Completed·DDirection Centrale du Service de Santé des Armées··NCT04408001·499 enrolled

Kidney Cancer1 trial

Biomarkers of Angiogenesis for Response to Therapeutic Combination in Advanced or Metastatic Kidney Cancer

Unknown status·AAssistance Publique - Hôpitaux de Paris··NCT05285579·100 enrolled

Unspecified2 trials

Pharmacogenetic DNA Bank

Unknown status·NNational University Hospital, Singapore··NCT00941200·5,000 enrolled

Study of Genetic Factors Other Than CYP2C9 and VKORC1 That Influence Warfarin Dose Requirements in a South-east Asian Population

Unknown status·NNational University Hospital, Singapore··NCT01050920

Sources

References

[1]
ClinicalTrials.gov — 23 trial records for Blood collection. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Blood collection compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Blood collection. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: AAssistance Publique - Hôpitaux de Paris

Blood collection

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q2 2027

Q1 2028

Q1 2029

Trials by Indication[1]

Age2 trials

Antibody1 trial

Dementia1 trial

Ankylosing Spondylitis1 trial

Rejection1 trial

Children1 trial

Hepatitis1 trial

Pulmonary Edema1 trial

Migraine1 trial

Recovery1 trial

Asthma1 trial

Stress1 trial

Colorectal Cancer1 trial

Antidepressants1 trial

Idiopathic Parkinson's Disease1 trial

Aspergillosis1 trial

Efficacy1 trial

Paclitaxel1 trial

COVID-191 trial

Kidney Cancer1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News